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The glucagon-like peptide-1 receptor (GLP-1R) is a key ther-
apeutic target in the management of type II diabetes mellitus,
with actions including regulation of insulin biosynthesis and
secretion, promotion of satiety, and preservation of-cell mass.
Likemost class BG protein-coupled receptors (GPCRs), there is
limited knowledge linkingbiological activity of theGLP-1Rwith
the molecular structure of an intact, full-length, and functional
receptorligand complex. In this study, we have utilized genetic
code expansion to site-specifically incorporate the photoactive
amino acid p-azido-L-phenylalanine (azF) into N-terminal resi-
dues of a full-length functional human GLP-1R in mammalian
cells. UV-mediated photolysis of azF was then carried out to
induce targeted photocross-linking to determine the proximity
of the azido group in themutant receptorwith the peptide exen-
din-4. Cross-linking data were compared directly with the crys-
tal structure of the isolated N-terminal extracellular domain of
theGLP-1R in complexwith exendin(9–39), revealingboth sim-
ilarities aswell as distinct differences in themode of interaction.
Generation of a molecular model to accommodate the photo-
cross-linking constraints highlights the potential influence
of environmental conditions on the conformation of the
receptorpeptide complex, including folding dynamics of the
peptide and formation of dimeric and higher order oligomeric
receptor multimers. These data demonstrate that crystal struc-
tures of isolated receptor regionsmaynot give a complete reflec-
tion of peptide/receptor interactions and should be combined
with additional experimental constraints to reveal peptide/re-
ceptor interactions occurring in the dynamic, native, and full-
length receptor state.
G protein-coupled receptors (GPCRs)4 are integral mem-
brane proteins that mediate transmembrane (TM) signaling in
response to a diverse range of extracellular stimuli, including
neurotransmitters, hormones, odorants, and light (1). Ac-
counting for as much as 2% of the human genome (2), GPCRs
have a fundamental role in almost all physiological functions
and as such have become key therapeutic targets in the treat-
ment ofmany disease states. Although almost one-third ofmar-
keted drugs act on GPCRs (3), very few target the small sub-
group of peptide-activated class B “secretin-like” receptors.
Despite this, class B GPCRs have been validated for the treat-
ment of a number of disease conditions, including depression
and anxiety (corticotropin-releasing factor (CRF) receptors),
osteoporosis (calcitonin and parathyroid hormone receptors),
andmetabolic disorders (glucagon-like peptide-1 (GLP-1), gas-
tric inhibitory polypeptide (GIP), glucagon (GCG), and amylin
receptors) (4). To fully unlock the therapeutic potential of this
receptor class, it is essential to understand not only the phar-
macology of these receptor systems in greater detail but also the
molecular and structural dynamics induced by peptide/recep-
tor interactions that underlie their functional outcomes.
Until recently, structural information for class B GPCRs was
limited to NMR and X-ray structures of isolated N-terminal
extracellular domains (ECDs) for several family members
(5–9), with homology modeling and mutagenesis data used to
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estimate the core TM-spanning region (10). Recent reports of
inactive TM crystal structures of the GCG receptor (GCGR)
(11, 12) and CRF1 receptor (CRF1R) (13) have since provided
significant improvement in understanding class B GPCRs,
revealing distinct orientations in TM bundle architecture com-
pared with class A GPCRs. Although crystallography is a pow-
erful technique in establishing receptor structure, this platform
only identifies static snapshots of highly dynamic entities. Fur-
thermore, none of the reported class B structures are of full-
length receptor proteins; N-terminal structures lack the entire
TM region, and TM structures have substantial N- and C-ter-
minal truncations. As with all documentedGPCR crystal struc-
tures, both GCGR and CRF1R were purified with large bulky
modifications (T4L for CRF1R and BRIL or T4L for GCGR),
multiple thermostabilizing mutations, and were crystallized in
the presence of small molecule antagonists (11–13). Conse-
quently, the information ascertained from these structuresmay
not give a complete account of native receptor configuration or
peptide/receptor interactions required to achieve the “active”
receptor conformations that drive intracellular signaling.
Beyond crystallography, investigation of peptide/receptor
interactions has principally involved receptor mutagenesis and
incorporation of photolabile probes into peptides (14). While
providing valuable insights, both strategies have limited inter-
pretability due to structural perturbations inflicted on the
receptor and peptide, respectively. More recently, genetic
incorporation of photoactive unnatural amino acids into recep-
tor proteins at putative peptide/receptor interaction points has
gained traction, because of high tolerability and low impact on
structural integrity (15–17). Furthermore, direct identification
of receptor binding contacts can be achieved by exploiting the
photocross-linking properties of the amino acid, as demon-
strated for several receptor proteins (15, 16, 18–22), and most
recently the serotonin transporter (23). Importantly, this
method can be conducted in mammalian cells (24–27), mim-
icking the native receptor environment.
The subject of this study, GLP-1R, plays a fundamental role
in controlling post-prandial insulin secretion upon interaction
with its cognate ligand, GLP-1, or exogenous peptides, such as
exendin-4 (28). Additionally, with a broad range of actions,
including promotion of insulin synthesis, decreasing GCG pro-
duction, preservation of pancreatic -cell mass, decreasing
appetite, and gastric emptying, as well as cardio- and neuropro-
tective functions (29, 30), the GLP-1R is an ideal target for
development of treatments for type II diabetes mellitus and
obesity. As such, comprehensive knowledge of peptide/recep-
tor interactions within this receptor system is vital in the devel-
opment of superior therapeutics to manage the condition.
In this study, we have successfully incorporated the photoac-
tive amino acid p-azido-L-phenylalanine (azF) into the human
GLP-1R at N-terminal ECD sites reported to interact with pep-
tide agonists (Table 1). Using the photocross-linking feature of
azF, we have mapped the principal binding region between the
GLP-1R N terminus and the exogenous peptide exendin-4 in
live cells expressing intactGLP-1R, andwe have used these data
to generate a detailedmodel of theGLP-1Rexendin-4 complex.
We observe that not all GLP-1R/exendin-4 interactions or
proximity estimates documented in the literature are consis-
tent with cross-linking data, demonstrating that crystal struc-
tures of isolated receptor regions (N-terminal or TM domains)
may not give a true reflection of peptide/receptor interactions
occurring in the dynamic, native, and full-length receptor state.
Expansion of this technology to include other GLP-1R peptide
ligands may allow for detection of subtle differences in recep-
tor/peptide interactions and binding domains, aiding our
understanding of the complexmolecular mechanisms underly-
ing the relationship between peptide binding and biased signal-
ing at the GLP-1R.
Results
Selection of humanGLP-1R residues for ambermutagenesis
and unnatural amino acid incorporation
To establish the peptide/receptor interface within the N-ter-
minal GLP-1R ECD, the unnatural amino acid azF was site-
specifically integrated into the humanGLP-1R using the amber
codon suppression technology in a recombinant HEK293T cell
system. This strategy exploits the ability of azF to covalently
link an interacting partner within close proximity (up to 3–4Å)
upon UV irradiation, and in this application a ligandreceptor
complex can be captured (Fig. 1A). Amino acid residues of
the GLP-1R chosen for amber mutagenesis and subsequent
azF incorporation encompassed both polar and non-polar,
charged, and aromatic amino acids (Fig. 1B), and they were
based on documented interactions between peptide agonists
and the N-terminal GLP-1R ECD through NMR and X-ray
crystallography (5, 6), as well as proximity analysis using p-ben-
zoyl-L-phenylalanine (Bpa)-labeled GLP-1 peptides (Table 1)
(31, 32).
Considerationwas also given to interacting residues reported
in relatedGIP receptor (GIPR) (9) andGCGR (12) crystal struc-
tures (Table 1). To validate the methodology, several GLP-1R
residues not documented to interact with peptide, and distal to
the predicted peptide-binding domain, were also selected for
azF incorporation.
AzFmutants are expressed at the cell surface in the presence
of azF supplementation
Cell-surface expression of azF-incorporated human GLP-1R
ambermutants was determined through immunological detec-
tion of the receptor N-terminal double c-Myc epitope (Fig. 2A).
Supplementation of transfected amber mutants with azF
resulted in cell-surface receptor expression ofmutants that was
statistically comparablewith that of thewild-type receptor con-
trol expressed at one-tenth that of mutants, with the exception
of W91azF that had significantly elevated expression and
E125azF that was poorly expressed (Fig. 2A and Table 2). In all
cases, low level cell-surface expression of amber mutants was
detected in the absence of azF supplementation, likely resulting
from incomplete efficiency in amber codon suppression,
instead incorporating endogenous Tyr at the amber codon site
during ribosomal elongation of the receptor product (Fig. 2A
and Table 2) (24). With the exception of E125azF, the level of
cell-surface expression of each receptor mutant in the absence
of azF was statistically lower than that observed in the presence
of azF, indicating successful incorporation of the azF residue
(Table 2). As noted previously (33), antibody (Ab) detection of
Photocross-linkingmaps exendin-4 binding on intact GLP-1R
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the N-terminal c-Myc epitope does not distinguish between
different receptor products, and therefore in the presence of
azF, a mixed population of both Tyr- and azF-incorporated
receptors are likely being detected at the cell surface. To
account for this, cell-surface expression of each receptor
mutant was corrected for that measured in the absence of azF,
allowing quantification of azF-dependent receptor expression
at the cell surface (Fig. 2B). Despite the overall reduction in
cell-surface expression as a result of this correction, all mutant
receptors maintained statistically comparable expression to
wild-type GLP-1R (Fig. 2B and Table 2), although azF-substi-
tutedTyr-42, Tyr-88,Glu-125, andGlu-127 all exhibited strong
trends toward lower comparative expression.
Functional impact of azF incorporation into the human
GLP-1R
Amber mutagenesis and incorporation of unnatural amino
acids such as azF have been observed to be well tolerated at
most receptor residues, at least in class A GPCR applications
(24, 25, 34). To determine whether this observation translated
into class B GPCRs, azF-incorporated GLP-1Rs were examined
for their ability to generate a cAMP response, a typical func-
tional readout directly correlated with insulin secretion in a
physiological setting (30). Consistent with that previously
reported (35), exendin-4 stimulated a robust cAMP response at
the wild-type GLP-1R, with a pEC50 value of 10.8 0.1 (Table
2). In the presence of azF, most mutant receptors were able to
generate an exendin-4-mediated cAMP response, with func-
tional affinity statistically comparable with wild-type control
(pEC50, Table 2 and supplemental Fig. S1). The exceptions to
this were T35azF, A70azF, L89azF, and P90azF that had 20-,
50-, 16-, and 8-fold decreases in potency, respectively, relative
towild-type control (Table 2). The loss of functional affinity did
not correlate with a decrease in total cell-surface expression
(Fig. 2A and Table 2), suggesting that the attenuation in func-
tionmay be a result of decreased ligand-binding affinity and/or
functional coupling at these receptor variants. The impact of
azF incorporation into the GLP-1R was more readily observed
in functional efficacy, with significant decreases in Emax for
exendin-4 at V30azF, S31azF, L32azF, Y42azF, Y69azF, Y88azF,
P90azF, L123azF, R134azF, and E138azF (Table 2 and supple-
mental Fig. S1). Despite the attenuated responses, thesemutant
receptors maintained statistically similar expression to wild
type, suggesting these residues are functionally or structurally
important. Notably, the functional response measured is likely
a composite of both azF- and Tyr-incorporated receptors, as
discussed above, and therefore deducing the population of azF-
incorporated receptors specific to the cAMP response is not
possible. Additionally, the method of cAMP detection in this
system is amplified such that even in the absence of azF the
ability of mutant receptors to generate an exendin-4-mediated
cAMP response is not always dissimilar to that in the presence
of azF (data not shown). Nonetheless, these data demonstrate
that inmost casesmutation to either azF or Tyr is generally well
tolerated by the receptor protein.
Functional impact of fluorescein (FL) incorporation into
GLP-1R peptide agonists
With the lack of robust Abs highly specific to any GLP-1R
peptide ligand, detection relies on conjugation or incorporation
of measurable probes into the peptide itself, such as biotin,
radioisotopes, or fluorophores. GLP-1 and GLP-1-related pep-
tides are sensitive to modification, particularly in the N-termi-
nal domain, which is required for efficient GLP-1R activation.
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Figure1. Schematic of azF-mediatedphotocross-linkingat theGLP-1Randaminoacidsmutated toazF in this study.A, all experimentswere conducted
on the human GLP-1R containing an N-terminal double c-Myc epitope following the signal peptide (residues 1–23), and a C-terminal V5 epitope. AzF is
incorporated at site-specific in-frame amber (TAG) mutations using a heterologous cell system and the amber codon suppressionmachinery detailed in Ye et
al. (24). Cells expressing azF-incorporated GLP-1Rs are incubated to equilibrium with FL-labeled exendin-4 (FL-exendin-4), followed by exposure to UV light
(365nm). Photoactivationof azFpromotes formationof a covalentbondwithprimary aminesor aliphatic hydrogens lyingwithin its proximity (up to3–4Å) (15,
18), allowing the receptor to capture the peptide. The receptorpeptide complex can then be immunologically detected using FL-specific Abs at a size that is
the sum of both components. B, schematic of the amino acids mutated to azF in the human GLP-1R, with three-letter and single-letter nomenclature in
parentheses.
Photocross-linkingmaps exendin-4 binding on intact GLP-1R
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Examples of this include exendin-4(1–39), a high affinity ago-
nist versus exendin(9–39), a high affinity antagonist, and GLP-
1(7–36)NH2, a high affinity agonist versusGLP-1(9–36)NH2, a
low affinity partial agonist (36). These data also indicate that
N-terminally modified exendin-4 retains efficient interaction
with the receptor despite loss of functional efficacy.
Radioisotopic labeling is a preferred method for many pep-
tide ligand applications, due to its ready detection and flexibility
in labeling via Tyr residues or Bolton-Hunter-mediated label-
ing of amides. However, the process of radiolabeling and sub-
sequent utilization of radiolabeled products in an experimental
setting is cumbersome, expensive, and hazardous. Conse-
quently, we elected to employ peptide ligands conjugated to FL,
a small yet intensely fluorescent probe that can also be detected
immunologically through use of Abs. FL was conjugated to the
exendin-4 peptide at the N terminus (FL-Ex4) or at amino acid
positions Trp-25 (FL(W25)-Ex4), Lys-27 (FL(K27)-Ex4), or
Arg-20 (FL(RK20)-Ex4, subsequently referred to as FL(K20)-
Ex4), the latter being synonymous with the position of hexade-
canoic acid (C16H32O2) modification in the GLP-1 mimetic,
liraglutide (37). Each modified exendin-4 analogue was
assessed for cAMP response at the wild-type human GLP-1R
(Table 3 and supplemental Fig. S2). Compared with native
exendin-4 (pEC50 11.0 0.1), addition of the FL moiety to the
N terminus of the peptide (FL-Ex4) significantly attenuated the
cAMPresponse, resulting in an500-fold reduction in potency
Table 1
AzF-substituted residues of the human GLP-1R studied for cross-linking and their previously documented interactions with peptide
Interactions are reported from isolated N-terminal domain crystal structures and previous cross-linking data. Equivalent residues for class B receptors are based on
homology alignment from Parthier et al. (9).
GLP-1R residue Reported interaction/sa Reported interactions in class B GPCR equivalent residues Refs.
Val-30 Ligand recognition/specificity 5
Gln-30 GIPR interacts with GIP 9
Ser-31 Ligand recognition/specificity 5
Leu-32 Ligand recognition/specificity 5
Ex(9–39) interaction point (F22)
GLP-1 interaction point (A24, A25,
and F28)
6
Ala-32 GIPR interacts with GIP 9
Trp-33 No documented interaction
Thr-35 Ex(9–39) interaction point (F22) 5
Leu-35 GIPR interacts with GIP 9
Val-36 Ex(9–39) interaction point (F22) 5
Tyr-36 GIPR interacts with GIP 9
Trp-39 Ex(9–39) interaction point (F22) 5
Trp-36 GCGR interacts with GCG 12
Conserved across GCG class B GPCRs Trp-39 GIPR interacts with GIP 9
Arg-40 No documented interaction
Tyr-42 No documented interaction 5
Conserved across GCG class B GPCRs
Phe-61 No documented interaction
Glu-68 Ex(9–39) interaction point (S32) 5
Met-67 GIPR interacts with GIP 9
Tyr-69 Ex(9–39) interaction point 5
GLP-1 interaction point (V33) 6
Tyr-68 GIPR interacts with GIP 9
Ala-70 No documented interaction
Phe-80 No documented interaction
Tyr-88 Ex(9–39) interaction point 5
Tyr-87 GIPR interacts with GIP 9
Leu-89 Ex(9–39) interaction point 5
Leu-88 GIPR interacts with GIP 9
Pro-90 Ex(9–39) interaction point (V19 and I23) 5
Pro-89 GIPR interacts with GIP 9
Trp-91 Ex(9–39) interaction point (V19 and I23) 5
Trp-90 GIPR interacts with GIP 9
Tyr-101 No documented interaction
Phe-103 No documented interaction
Ser-116 No documented interaction
Ser-117 No documented interaction
N-Glycosylation recognition domain 49
Leu-118 No documented interaction
Pro-119 Putative GLP-1 interaction point 6
Arg-121 Ex(9–39) interaction point (K27) 5
GLP-1 interaction point (V33) 6
Arg-113 GIPR interacts with GIP 9
Leu-123 Ex(9–39) interaction point 5
GLP-1 interaction point (V33) 6
His-115 GIPR interacts with GIP 9
Ser-124 No documented interaction
Glu-125 Proximal to GLP-1 peptide
(cross-linking) (Bpa35)
31
Glu-127 Ex(9–39) interaction point (K27 and E24) 5
No documented GLP-1 interaction 6
Arg-134 No documented interaction
Ser-135 No documented interaction
Glu-138 No documented interaction
a Peptide residue number is denoted in superscript following single code amino acid.
Photocross-linkingmaps exendin-4 binding on intact GLP-1R
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(Table 3), likely as a result of disruption to the positioning of the
peptideN terminus within the receptor core. Significant reduc-
tions in potency were also observed for FL(K20)-Ex4 and
FL(K27)-Ex4, albeit the fold reduction was not as severe as that
for N-terminal FL addition (50- and 16-fold, respectively),
whereas FL(W25)-Ex4 did not significantly deviate from the
unmodified peptide (Table 3).
Mapping the exendin-4-binding site in the humanGLP-1R N
terminus using azF-mediated photocross-linking in live cells
As detailed above, azF incorporation at site-specifically
introduced amber codons is not 100% efficient, allowing incor-
poration of endogenous Tyr (24). Nonetheless, this does not
impact on the application of the targeted photocross-linking
method, as only azF-incorporated receptors have the ability to
covalently capture close proximity partners upon UV activa-
tion. Cells transiently expressing humanGLP-1Rwith site-spe-
cifically incorporated azF were equilibrated with 100-fold the
functional affinity (pEC50; as determined through cAMP accu-
mulation) of each FL-conjugated exendin-4 peptide and irradi-
ated with UV light (365 nm). Resultant azF-mediated cross-
links between peptide and receptor were determined through
immunodetection of the FL moiety occurring at the size of the
peptidereceptor complex (65 kDa (monomeric receptor) and
150 kDa (dimeric receptor)). Interpretation of cross-linking
profiles for each of FL(K20)-Ex4, FL(W25)-Ex4, and to a lesser
extent FL(K27)-Ex4 to azF-incorporated GLP-1Rs was prob-
lematic due to weak signal obtained when probing for FL
(data not shown), potentially because of formation of a
peptidereceptor complex that buries the FL moiety within a
region inaccessible, or only partially accessible, by the FL-di-
rectedAb. For these analogues, the location of FL incorporation
within the exendin-4 peptide also likely occurs in a region of the
peptide that binds the receptor N terminus, impacting accurate
interpretation of interactions between exendin-4 and the
GLP-1R N terminus using the cross-linking method (supple-
mental Fig. S3). For these reasons, the FL(K20)-Ex4 and
FL(W25)-Ex4 analogues were not pursued further for photo-
Figure 2. Cell-surface expression profiles of azF-incorporated GLP-1R amber mutants. A, cell-surface expression of each of the human GLP-1R amber
mutants transiently transfected into HEK293T cells in the absence (open bars) and presence (closed bars) of 0.5mM azF, as determined throughAb detection of
theN-terminal double c-Mycepitope.B,azF-dependent cell-surfaceexpressionof eachof thehumanGLP-1Rambermutants, corrected for receptor expression
observed in the absence of azF. Data are normalized to the cell-surface expression measured for wild-type human GLP-1R, transfected at one-tenth that of
mutants (100%), anderrorswerepropagated frombothazF andazF. Changes in cell-surface expression for eachmutant in the absence andpresenceof azF
was determined using an unpaired t test, and statistical significance was accepted as p  0.05 (*). Changes in azF-dependent cell-surface expression in
comparison with wild-type control was determined by one-way analysis of variance and Dunnett’s post-test, and statistical significance was accepted as p
0.05 (**). All data are mean S.E. of three to eight independent experiments, conducted in duplicate.
Photocross-linkingmaps exendin-4 binding on intact GLP-1R
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cross-linking, whereas FL(K27)-Ex4 was limited to confirma-
tory studies. Despite the lower functional affinity observed for
FL-Ex4 at the GLP-1R compared with the other exendin-4 ana-
logues (Table 3), this peptide robustly cross-linked to multiple
azF-incorporated GLP-1Rs in a UV-dependent manner (Fig.
3A). As observed previously (16, 18), there was no cross-linking
between receptor and peptide in the absence of azF supplemen-
tation or in the absence of UV exposure (Fig. 3A, data not
shown). Homologous competition with increasing concentra-
tions of unlabeled exendin-4 almost completely abolished for-
mation of the GLP-1RFL-Ex4 complex, whereas the pre-
formed, UV-cross-linked GLP-1RFL-Ex4 complex was not
disrupted by excess unlabeled exendin-4, suggesting that
FL-Ex4 occupies a similar binding cavity to unlabeled exen-
din-4, as well as confirming the covalent nature of azF-medi-
ated cross-links (supplemental Fig. S4, A and B and data not
shown). Interestingly, cells expressing the wild-type GLP-1R
sporadically displayed UV-mediated nonspecific cross-linking
with FL-Ex4 in both the presence and absence of azF (supple-
mental Fig. S4, A and B). These phenomena were not isolated
artifacts of FL-Ex4, as nonspecific cross-linking of FL(K27)-Ex4
was also observed, albeit the strength of signal was proportion-
ally lower (supplemental Fig. S4, C and D). In both cases, the
level of cross-linking observed at the wild-type receptor was
consistently lower than that of azF-incorporated receptors,
despite similar levels of expression (Fig. 2 and Table 2). Subse-
quent determination and quantification of specific FL-Ex4
Table 2
Summary of the effects of azF incorporation into the human GLP-1R
HEK293T cells transiently expressing human GLP-1R wild-type or amber mutants in the absence () and presence () of 0.5 mM azF are shown. Total cell-surface
expression was determined through Ab detection of the N-terminal c-Myc epitope label, with data expressed as a maximum of wild-type human GLP-1R expression.
AzF-dependent cell-surface expression was determined through baseline correction to the expression observed for each mutant receptor in the absence of azF, with data
expressed as a maximum of wild-type human GLP-1R expression and errors propagated from both azF and azF conditions. Exendin-4-mediated cAMP data were
analyzed using a three-parameter logistic equation as defined in Equation 1. pEC50 values represent the negative logarithmof the concentration of agonist that produces half
the maximal response. Emax represents the maximal response normalized to that elicited by 10 M forskolin. Relative cross-linking of FL-Ex4 at receptor mutants was
determined as a measure of optical density, normalized to the respective controls on the same blot. Values are expressed as mean  S.E. of three to eight independent
experiments, conducted in duplicate or triplicate. Cell surface expression of each mutant receptor in the absence and presence of azF supplementation was analyzed using
an unpaired t test, and statistical significance was accepted as p 0.05 (bold, *). All other data were analyzed with one-way analysis of variance and Dunnett’s post-test, and
statistical significance accepted as p 0.05 in comparison with wild-type control (bold, **). ND, not detected.
Cell surface expression
(% wild type)
azF-dependent
cell-surface expression
(% wild type)
cAMP (Exendin-4)
(azF) Specific cross-linking
(% Y69azF)azF azF azF pEC50 Emaxa
Wild typeb 99.9 0.1 100.0 0.1 100.0 0.1 10.8 0.1 64.5 2.2 ND
V30azF 29.6 7.0 137.5 19.6* 107.8 20.8 11.2 0.3 45.5 3.3** 143.5 27.7
S31azF 23.4 4.0 86.6 9.6* 63.2 10.4 11.1 0.2 54.1 3.0** 74.1 12.7
L32azF 23.6 3.5 102.9 14.6* 79.3 15.0 11.1 0.3 48.0 3.1** 194.1 46.1
W33azF 34.5 8.3 124.9 10.6* 90.4 13.5 11.4 0.1 66.4 2.2 115.2 41.2
T35azF 12.3 1.5 88.5 8.3* 76.3 8.4 9.5 0.2** 59.2 3.6 ND
V36azF 45.1 7.0 137.4 7.2* 92.3 10.0 11.4 0.1 63.8 2.3 78.7 40.3
W39azF 45.7 5.4 134.6 12.0* 88.9 13.2 10.6 0.2 61.2 2.7 ND
R40azF 24.5 2.5 113.0 8.2* 88.6 8.5 11.5 0.1 62.3 1.9 80.9 26.5
Y42azF 30.0 8.1 79.3 12.6* 49.4 15.0 10.6 0.2 37.4 2.2** ND
F61azF 36.1 8.3 142.4 28.5* 106.3 29.7 11.3 0.2 67.5 2.6 6.2 4.8
E68azF 22.1 1.2 104.6 11.9* 82.5 12.0 11.4 0.2 70.9 2.6 31.2 6.8
Y69azF 40.5 9.4 114.1 15.0* 73.7 17.7 10.8 0.3 29.2 2.0** 100
A70azF 18.9 1.5 127.3 14.8* 108.3 14.9 9.1 0.1** 69.1 2.8 ND
F80azF 19.0 7.0 102.6 27.8* 83.6 28.6 11.3 0.2 69.0 2.8 53.1 13.4
Y88azF 43.7 6.0 96.3 12.0* 52.6 13.4 10.6 0.2 28.2 1.7** ND
L89azF 35.3 5.8 105.0 12.3* 69.7 13.6 9.6 0.1** 70.4 2.6 ND
P90azF 27.8 4.2 93.7 19.1* 65.9 19.6 9.9 0.2** 51.1 4.0** ND
W91azF 39.1 9.9 196.2 23.1*,** 157.0 25.2 11.5 0.2 64.4 3.6 8.5 5.0
Y101azF 43.5 7.5 112.9 28.0* 79.2 29.3 11.5 0.2 62.1 2.3 36.9 17.1
F103azF 45.9 8.2 139.9 18.4* 96.5 19.8 11.4 0.2 55.8 2.1 51.3 17.2
S116azF 28.9 16.5 132.6 21.0* 103.7 26.7 11.4 0.1 69.3 1.6 16.3 6.9
S117azF 23.5 12.2 119.8 11.6* 96.3 16.8 11.1 0.2 64.2 2.8 52.5 17.7
L118azF 57.3 15.6 121.1 14.3* 63.8 21.2 11.5 0.1 72.4 1.8 99.6 24.5
P119azF 40.1 1.8 109.0 7.8* 68.9 8.0 11.4 0.1 71.7 1.5 ND
R121azF 53.6 12.0 131.7 25.4* 78.1 28.1 10.0 0.1 71.6 1.9 ND
L123azF 26.4 13.6 107.1 15.8* 80.7 20.9 11.2 0.3 19.9 1.5** 145.3 30.8
S124azF 33.4 6.0 109.4 12.5* 76.0 13.9 11.4 0.1 72.2 1.9 ND
E125azF 28.8 11.3 46.0 4.7 17.2 12.3 10.3 0.1 66.4 2.5 ND
E127azF 42.0 7.0 82.0 10.3* 40.1 12.5 10.8 0.1 76.8 2.0 128.8 59.2
R134azF 14.4 8.2 125.4 15.4* 111.0 17.4 11.1 0.3 40.5 3.4** 102.4 29.2
S135azF 31.2 11.9 154.5 27.7* 123.2 30.1 11.5 0.1 75.7 2.6 48.4 8.1
E138azF 34.0 12.1 109.8 21.3* 75.8 21.3 11.0 0.3 39.2 2.7** ND
a The Emax values are represented as the maximal response normalized to that elicited by 10 M forskolin.
b The wild-type human GLP-1R was transfected at one-tenth that of mutant receptors.
Table 3
Effect of FL incorporation into exendin-4 on cAMP accumulation in
HEK293T cells transiently expressing the human GLP-1R
Datawere analyzed using a three-parameter logistic equation as defined in Equation
1. pEC50 values represent the negative logarithmof the concentration of agonist that
produces half themaximal response.Emax represents themaximal response normal-
ized to that elicited by 10M forskolin. Values are expressed asmean S.E. of three
to six independent experiments, conducted in duplicate or triplicate. Data were
analyzed with one-way analysis of variance and Dunnett’s post-test, and statistical
significance accepted as p 0.05 in comparison to the unmodified peptide (bold, *).
pEC50 Emax
Ex4 11.0 0.1 64.4 1.9
FL-Ex4 8.3 0.2* 44.6 4.6*
FL(W25)-Ex4 10.5 0.1 66.5 2.0
FL(K20)-Ex4 9.3 0.1* 60.9 2.1
FL(K27)-Ex4 9.8 0.2* 66.4 6.0
Photocross-linkingmaps exendin-4 binding on intact GLP-1R
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cross-linking to azF-incorporated GLP-1Rs therefore involved
correction for background signal occurring at the wild-type
GLP-1R. To account for variation across individual experi-
ments, data were also normalized to the level of cross-linking
observed with Y69azF that was run as a control in each exper-
iment. Of the residues analyzed in this study, robust cross-link-
ing was observed between FL-Ex4 and GLP-1R mutants
V30azF, S31azF, L32azF, W33azF, V36azF, R40azF, E68zF,
Y69azF, F80azF, Y101azF, F103azF, S117azF, L118azF, L123azF,
E127azF, R134azF, and S135azF (Fig. 3 and Table 2), although
weak and inconsistent cross-linking was observed for S116azF
in some experiments (Fig. 3 and Table 2). Weak or no interac-
Figure 3. Mapping the exendin-4-binding site within the human GLP-1R N terminus using azF-mediated cross-linking. A, photocross-linking of azF-
incorporated GLP-1Rs with FL-Ex4. HEK293T cells transiently expressing each of the humanGLP-1R ambermutants in the absence () and presence () of 0.5
mM azF were incubated with 10 nM FL-Ex4 followed by exposure to UV light for 2 min at 4 °C. Whole-cell lysates were then immunoprecipitated (IP) using an
anti-V5 Ab to isolate full-length GLP-1Rs, and products were resolved by SDS-PAGE. Bands detected with the anti-FL Ab (immunoblot, IB) identify receptor
positions at which azF covalently captures the FL-Ex4 ligand. Non-cross-linked FL-Ex4 was not detected (4.5 kDa). Data are representative of three to eight
independent experiments. B, comparison between azF-dependent cell-surface expression of human GLP-1R amber mutants and relative photocross-linking
with FL-Ex4. azF-dependent cell-surface expression of human GLP-1R ambermutants transiently transfected into HEK293T cells in the presence of 0.5mM azF
(closed bars, above x axis) was determined through Ab detection of the N-terminal double c-Myc epitope. Data are corrected for cell-surface expression
measured in the absence of azF, normalized to the wild-type GLP-1R control transfected at one-tenth that of mutants, and subsequently normalized to the
azF-dependent cell-surface expression measured for Y69azF (100%, internal control). Relative cross-linking of FL-Ex4 at human GLP-1R amber mutants
transiently transfected into HEK293T cells in the presence of 0.5 mM azF (gray bars, below x axis) was determined as a measure of optical density of the band
corresponding to the monomeric receptorligand complex (65 kDa), normalized to the respective wild-type control on the same blot, and subsequently
normalized to the optical density measured for Y69azF on the same blot (100%, internal control). All data are mean  S.E. of three to eight independent
experiments. N.D., not detected. C, summary of human GLP-1R N-terminal ECD residues determined in this study to cross-link with FL-Ex4.
Photocross-linkingmaps exendin-4 binding on intact GLP-1R
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tions were identified between FL-Ex4 and GLP-1R mutants
T35azF, W39azF, Y42azF, F61azF, A70azF, Y88azF, L89azF,
P90azF, W91azF, P119azF, R121azF, S124azF, E125azF, and
E138azF (Fig. 3 and Table 2). The relative level of cross-linking,
as determined through densitometry analysis, did not directly
correlate with azF-dependent expression of mutant receptors;
for example, S135azF had low level cross-linking with FL-Ex4
but trended toward increased expression compared with the
wild-type receptor, and E127azF was highly efficient in cross-
linking with FL-Ex4 but had low expression relative to the wild-
type control (Figs. 2B and 3B). Of note, most mutants that dis-
played high levels of cross-linking exhibited decreases in
exendin-4-mediated cAMP responses, including V30azF,
L32azF, Y69azF, L123azF, and R134azF that was unrelated to
their level of cell-surface receptor expression (Fig. 3B and sup-
plemental Fig. S1), althoughW33azF and E127azF were excep-
tions to this trend.
Comparison of the GLP-1R-FL-Ex4 cross-linking profile with
the isolated GLP-1R N-terminal exendin(9–39) crystal
structure
Using the crystal structure of the isolated N-terminal
GLP-1R ECD in complex with the C-terminal exendin frag-
ment, exendin(9–39) (PDB 3C59 (5)), we have identified recep-
tor residues within 5 Å of the peptide (Fig. 4A) and compared
these to the receptor residues that formed cross-links with
FL-Ex4 (Fig. 4B). Although there was significant overlap in the
peptide-binding surface of the crystal structure and sites of
cross-linking, including V30azF, S31azF, L32azF, V36azF,
E68azF, Y69azF, L123azF, and E127azF, there was also marked
divergence in the patterns of interaction. Notably, Thr-35, Trp-
39, Tyr-88, Leu-89, Pro-90, Trp-91, and Arg-121 that contrib-
uted to the binding surface for exendin(9–39) each failed to
cross-link to FL-Ex4 when mutated to azF. Furthermore, there
was a range of azF-modified residues that formed cross-links
that were not proximal to exendin(9–39) in the isolated N-ter-
minal ECD complex: W33azF, R40azF, F80azF, Y101azF,
F103azF, S117azF, and L118azF. Strong cross-linking was also
observed for R134azF and to a lesser extent S135azF that are
part of the TM1-ECD stalk but are absent from the isolated
N-terminal ECD structure. Of note, there is a high degree of
overlap in the location of ECD residues proximal to the peptide
for the solved ECD structures of the GLP-1R and GIPR (Fig. 5)
(5, 9), implying that lack of constraints imposed by interactions
of the N-terminal ECD and receptor core may have similar
impact for members of at least the GCGR subfamily.
Generation of a GLP-1R N-terminal exendin-4molecular
model to accommodate photocross-linking constraints
Using an experimentally validated GLP-1R model as a tem-
plate (38, 39), a refined GLP-1R N-terminal exendin-4 model
was generated to accommodate the photocross-linking data
(Fig. 6A). This model revealed a potential for the C terminus of
exendin-4 to “snake” over the top of the ECD to interact with
Phe-80, Tyr-101, and Phe-103. Because an N-terminally modi-
fied FL-Ex4 was used for cross-linking, confidence that these
observations were not due to altered binding of the peptide to
the receptor core by the FLwas achieved by comparisonwith an
internally labeled exendin-4 peptide. Although FL(K27)-Ex4
has poor cross-linking efficiency, a specific signal could be
engendered with high levels of the peptide. Under these condi-
tions, a similar level of cross-linking to F80azF, Y101azF, and
Figure 4. Comparison of the interaction surface of the human GLP-1R N
terminuswithexendin-4, as identifiedby crystallographyandazF-medi-
ated cross-linking. A, crystal structure of the isolated N-terminal ECD of the
human GLP-1R in complex with exendin-4 (PDB code 3C59). The interaction
surface of the receptor (within 5 Å of exendin-4) is shown in blue; the back-
bone of the receptor N terminus is shown as a pink ribbon, and the backbone
of the exendin-4 peptide as a dark gray ribbon. B, azF-substituted residues of
the full-length human GLP-1Rmapped to the crystal structure of the isolated
human GLP-1R N terminus in complex with exendin-4 (PDB code 3C59). Res-
idues cross-linking to FL-Ex4 are displayed in surface representation, colored
according to strength of cross-linking (red, strong; dark orange, moderate;
light orange, weak). azF-substituted residues that did not cross-link to FL-Ex4
are shown in wire representation, colored navy blue. The backbone of the
receptor N terminus is colored in off-white ribbon, and the backbone of the
exendin-4 peptide in dark gray ribbon.
Figure 5. GIP and exendin-4 occupy a similar groove and make con-
served contacts with their respective receptors in X-ray crystal struc-
tures of the isolated N-terminal ECDs. Left panel, GIP (blue) and exendin-4
(green) are shown as ribbon and wire representations covered by a transpar-
ent surface.Rightpanel,enlarged representationof theGIPR (PDBcode2QKH)
andGLP-1R (PDB code 3C59) illustrating amino acid residueswithin 5 Å (illus-
trated by ball and stick representation) of either GIP or exendin-4, respec-
tively. The extensions of the highlighted amino acids outside of the 5 Å dis-
tance are illustrated by gray wire representation.
Photocross-linkingmaps exendin-4 binding on intact GLP-1R
7138 J. Biol. Chem. (2017) 292(17) 7131–7144
 at U
N
IV
ERSITY
 O
F ESSEX
 on M
ay 12, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
F103azF, relative to the reference Y69azFmutant, was observed
for both FL(K27)-Ex4 and FL-Ex4, demonstrating that this
cross-linking was not an artifact of N-terminal FL labeling of
the peptide (supplemental Fig. S5). Notably, the GLP-1R also
forms functionally important homodimers along the interface
of TM4 (40), and as such, we also modeled receptor dimers and
higher order oligomers (Fig. 6B). A dimer of dimers model
based on a principle TM4 interface would also place the C ter-
minus of exendin-4 in close proximity to Phe-80, Tyr-101, and
Phe-103 of the adjacent dimeric receptor, making cross-dimer
cross-linking a plausible explanation for the cross-linking data.
Discussion
GPCRs all share similar structural architecture that includes
seven -helical TM domains connected by intra- and extracel-
lular loops, an extracellular N-terminal domain, and an intra-
cellular C-terminal domain (41). Despite these similarities,
GPCRs possess unique structural and functional elements, and
as such can be subdivided into different classes. In the absence
of the full-length, unmodified, active receptor crystal structures
for class B GPCRs, there remains significant ambiguity with
respect to the mechanistic link betweenmolecular interactions
occurring at the receptor-peptide level and generation of dis-
tinct cellular responses. We begin to address this ambiguity
through application of azF-mediated targeted photocross-link-
ing to the therapeutically important class BGLP-1R, identifying
interactions occurring between the receptor and an exogenous
peptide in mammalian cells. This allowed for generation of
molecular detail of the interactions occurring in a functionally
active receptorligand complex in an innate setting. Although
mostly analogous with published structures, several distinct
differences were identified that may be important in the pro-
gression of structural and functional studies not only of the
GLP-1R but also more broadly into the larger subgroup of class
B receptors.
All 32 amber mutants generated in this study were trafficked
to the cell surface in the presence of azF supplementation,
although E125azFwas not significantly different from theazF
control, andmost induced a robust cAMP response in the pres-
ence of exendin-4. These data indicate that azF incorporation
into the GLP-1R is generally well tolerated and that amber
codon suppression technology is suitable for investigation of
this highly dynamic and unstable receptor protein. The obser-
vation of expression and function of amber mutants in the
absence of azF was perhaps not surprising, given thatmisincor-
poration of endogenous Tyr in themammalian systemhas been
documented to occur (24).
Interestingly, the peptide-binding groove for the GLP-1R,
and indeedmost class BGPCRs, is principally hydrophobic, and
loss of direct interactions in this region would not be predicted
to havemajor effects on peptide affinity. This is mirrored in the
relatively limited impact of azF substitution on exendin-4
potency andEmax in cAMP signaling (Table 2 and supplemental
Fig. S1). In all cases, reductions in Emax occurred in the absence
of potency changes, indicating that there was no receptor
reserve with the low levels of GLP-1R expression achieved
under amber suppression. Reduced Emax, in the absence of
potency changes, likely reflects alterations in the presentation
of the peptideN terminus to the receptor core that is critical for
receptor activation. Mutations that affected exendin-4 Emax
broadly fell into two categories as follows: (i) residues that
reside at the extremes of the ECD (V30azF, S31azF, and L32azF
at the farN terminus and R134azF and E138azF that are located
near the boundary of theN-terminal ECD andTM1) consistent
with peptide interactions contributing to receptor activation,
and (ii) residues within the hydrophobic core of the ECD,
including three Tyr residues (Y42azF, Y69azF, Y88azF, and
L123azF). These Tyr residues are important for packing and
tertiary structure of the ECD, with Ala mutation resulting in
complete loss of function (6). AzF and Tyr are identical except
for the functional group in the para-position of the phenyl ring,
azido (N3), and hydroxyl (OH), respectively (Fig. 1B), and
may indicate a role for H-bonding to the hydroxyl in mainte-
Figure 6.Molecularmodelingof the interaction interfacebetween theN-terminal ECDof thehumanGLP-1Randexendin-4usingphotocross-linking
constraints. A, predicted binding path of the exendin-4 peptide (gray surface representation) with the N-terminal ECD of the human GLP-1R (ruby ribbon
representation). Residues positive for photocross-linking are highlighted in pink and yellow VDW representation. The C terminus of exendin-4 peptide may
snake over the top of the ECD to interact with Phe-80, Tyr-101, and Phe-103 of the receptor (yellow VDW representation). B, top view of dimer of dimersmodel.
HumanGLP-1Rs formhomodimers across the TM4 interface (40). Residuesof TM4 involved indimerization arehighlighted in coral (top) and cyan (bottom) VDW
representation. N-terminal ECDs of each receptor monomer are illustrated in ribbon representation in a darker shade than their corresponding TM domain
color. Exendin-4 is illustrated in gray surface representation and potentially interacts with Phe-80, Tyr-101, and Phe-103 (yellow VDW representation) of the
adjacent receptor dimer. The numbers 4 and 5 identify TM4 and TM5, respectively.
Photocross-linkingmaps exendin-4 binding on intact GLP-1R
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nance of the optimal tertiary structure.Only four azFmutations
(T35azF, A70azF, L89azF, and P90azF) resulted in loss of
potency that, under the conditions of assay (no reserve), reflects
decreased functional affinity for exendin-4. This could be due
to effects on ligand/receptor interaction or to conformational
changes to the N-terminal ECD that alter binding affinity. In
accord, none of these mutants displayed cross-linking to
FL-Ex4. In the GLP-1R ECD crystal structure, Ala-70 is posi-
tioned in the core of the peptide-binding domain, and it is likely
that a small amino acid is required at this position to facilitate
hydrophobic packing. Leu-89 is also important for ECD struc-
ture, with L89A mutation abolishing GLP-1 peptide binding
(6); however, there is limited interaction between this amino
acid and exendin(9–39) in the N-terminal ECD crystal struc-
ture complex, and as such the lack of cross-linking could also be
due to decreased affinity for FL-Ex4, rather than lack of prox-
imity to the peptide. This may also be true for T35azF and
P90azF. T35A significantly increases exendin-4 binding, and
P90A significantly decreases exendin-4-mediated signaling (6),
consistent with a role for these amino acids in either peptide
binding or N-terminal ECD conformation.
For all other mutants, exendin-4 potency and Emax were
unaltered, suggesting that the mutations did not alter receptor
conformation and that cross-linking (or absence thereof) pro-
vided specific information about the proximity of the peptide
and the N-terminal ECD in an intact functional receptor. The
exception was E125azF, where no significant difference in cell-
surface expression was observed in the presence and absence of
azF supplementation (Fig. 2A), indicating poor incorporation
or tolerance of azF at this position. Although not explicitly
reported to interact with exendin-4, Glu-125 has been noted as
a putative interaction site for theGLP-1 peptide throughBpa35-
GLP-1 photolabeling (31). In these studies, cross-linking can
occur across larger distances (10 Å) (31, 42), although the
distance betweenGly-35 of GLP-1 andGlu-125 in the GLP-1R-
GLP-1 isolated ECD crystal structure of 23 Å is outside the
proximity required for photolabeling. Mutation of Glu-125 to
Ala did not significantly impact GLP-1 binding affinity or func-
tion (31, 43, 44), and thus, Glu-125 does not form an interaction
with peptide that is essential for receptor function.
The isolatedN-terminal ECDGLP-1R structure lacks biolog-
ical context, in particular, the physical contiguity of the peptide
backbone from the TM domain core (extending from TM1)
and potential interactions of the far N terminus of the ECD, as
have been predicted in simulations of GLP-1R-GLP-1 (38) and
in models of GLP-1R activation based on activity of tethered
peptides (45). Such ECD and TM core interactions are also
predicted from activity of inverse-agonist Abs that bind to the
ECD of the GCGR (46). Although there were major overlaps of
sites of cross-linking in our study and residue proximity in the
isolated ECD structure (Val-30, Ser-31, Leu-32, Val-36, Glu-68,
Tyr-69, Leu-123, and Glu-127), there were clear differences,
including Thr-35, Trp-39, Tyr-88, Leu-89, Pro-90, Trp-91, and
Arg-121, that contributed to the binding surface for ex-
endin(9–39) but did not cross-link, and Trp-33, Arg-40, Phe-
80, Tyr-101, Phe-103, Ser-117, and Leu-118 that exhibited
cross-linking but were oriented away from the peptide in the
crystal structure (5).
Our data indicate that in the context of the intact receptor,
the far N-terminal helix of the ECD is extended toward the
receptor core with a rotation of the helix toward the peptide,
and that this is accompanied by closure of the binding groove
bounded by Tyr-69, Leu-123, and Glu-127 that would be con-
sistent with the requirement for physical contiguity of the pep-
tide backbone with the top of TM1. This could also move resi-
dues Thr-35, Trp-39, Tyr-88, Leu-89, Pro-90, and Trp-91 away
from the peptide interface observed in the crystal structure,
while bringing Trp-33 and Arg-40 into closer proximity. Muta-
tion of Arg-40 to Ala resulted in a small decrease in binding
affinity ofGLP-1 (47), which is consistentwith a potential direct
interaction with peptides. Arg-134 and Ser-135 are not present
in the crystal structure but are located in the TM1 stalk/ECD
boundary and further support closure of the groove in the full-
length receptor. Although Thr-35 may still potentially form
interactions with the peptide (as discussed above), mutational
data for Trp-39 are consistent with our proposed model. In the
ECD crystal structure, Trp-39 is oriented away from the core
domain and forms weak hydrophobic interactions with
exendin(9–39) (5) that would be expected to have only limited
impact on peptide affinity. In contrast, mutation of Trp-39 to
Ala or Phe resulted in loss of detectable GLP-1 binding, despite
maintaining expression comparable with the wild-type recep-
tor (47, 48). Similarly,mutation of the equivalentGCGR residue
Trp-36 toAla resulted in no detectable binding ofGCG, despite
significantly increased expression compared with the wild-type
receptor (12). These data imply that, like other key hydrophobic
residues, Trp-39 is essential to ensure correct folding/confor-
mation of the ECD, and rotation of the N-terminal ECD helix
would position Trp-39 toward the core of the ECD.
The position of cross-linking residues at amino acid Ser-117
and Leu-118 is consistent with potential extension of the C
terminus of exendin-4, with the N-terminal ECD GLP-1R-
exendin(9–39) structure lacking density for amino acids 34–39
of the peptide (5). These results imply that this segment is rel-
atively mobile, and the interaction of exendin-4 is readily
accommodated in molecular models of the full-length receptor
(Fig. 6). Interestingly, Ser-117 is part of the Asn-115/Ser-116/
Ser-117 consensus glycosylation site within the GLP-1R (Fig.
3C) (49), with mutation predicted to disrupt glycosylation.
S117azF hadwild-type behavior in function, indicating that gly-
cosylation at this site is not required for receptor expression
and function, and this is consistent with the N115L mutation
that had wild-type expression and function (50). Asn-115 is
positioned away from the ECD core, and glycosylation at this
site would be unlikely to interfere with peptide/receptor
interactions.
Themost intriguing finding of this study was the weak cross-
linking to positions Phe-80, Tyr-101, and Phe-103 that are con-
tiguous in 3D space but are located on the “back” face of the
N-terminal ECD, away from the primary peptide-binding
groove. These residues have not previously been documented
to form interactions with any peptide ligand of the GLP-1R and
are located in a region distal to the peptide-binding domain as
determined by isolated N-terminal ECD structures (5, 6). As
mentioned above, the N-terminal crystal structure of the GLP-
1Rexendin complex excludes six C-terminal residues of the
Photocross-linkingmaps exendin-4 binding on intact GLP-1R
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peptide (GAPPPS) (5). This Pro-rich fragment is fundamental
to the formation of the “Trp-cage,” a compact hydrophobic
“cage” arrangement encasing Trp-25 of the exendin-4 peptide.
However, the conformation and dynamics of the Trp-cage is
largely dependent on the environmental conditions (51–55),
and in the context of a cellular setting, it may therefore poten-
tially exist in a landscape of both a compact rigid state and a
more disordered flexible state. The lattermay then allow for the
C terminus of the peptide to snake back over the top of the ECD
to form interactions with Phe-80, Tyr-101, and Phe-103 (Fig.
6A). However, with the ability of the GLP-1R to form
homodimers along the interface of TM4 (40), a dimer of dimers
model also accounts for cross-linking between exendin-4 and
Phe-80, Tyr-101, and Phe-103 of the adjacent dimeric receptor
(Fig. 6B). Furthermore, Glu-125 is located on the same face of
the ECD as Phe-80, Tyr-101, and Phe-103, and a dimer of
dimers model would place this residue in a position that would
be compatible with the Bpa-mediated cross-linking with posi-
tion 35 of the GLP-1 peptide (31), as discussed above. Notably,
GLP-1 is shorter than exendin-4 and would not be able bridge
the distance by snaking of the C terminus toward the top of the
ECD.
In this study, we have used the powerful technique of recep-
tor-based targeted photocross-linking to investigate themolec-
ular interactions occurring between the exendin-4 peptide and
the N-terminal ECD of the full-length, fully functional human
GLP-1R inmammalian cells, thereby simulating a native recep-
tor environment. Our data provide novel insights into the
dynamics of peptide interaction with the receptor that contrib-
ute to linking receptor structure with molecular function and
the pursuit of structure-based drug design.
Experimental procedures
Materials
DMEM, PBS, Hanks’ buffered salt solution (HBSS), Lipo-
fectamineTM reagent, PLUSTM reagent, NuPAGE 4–12% Bis-
Tris protein gels and buffers, DynaBeads protein G, chemilu-
minescent substrate, and monoclonal mouse anti-V5 Ab
(R960-25) were purchased from Life Technologies, Inc. Poly-
clonal rabbit anti-FL Ab (ab19491) was purchased fromAbcam
(Cambridge, MA). The QuikChange Lightning site-directed
mutagenesis kit was purchased from Stratagene (La Jolla, CA).
AzF was purchased from Chem Impex International (Wood
Dale, IL). Exendin-4 was purchased from American Peptide
(Sunnyvale, CA). FL-labeled exendin-4 analogues were pur-
chased from Anaspec (Fremont, CA) and NeoScientific (Cam-
bridge, MA). AlphaScreenTM reagents and 384-well Proxi-
Plates were purchased from PerkinElmer Life Sciences.
SigmaFastTM o-phenylenediamine dihydrochloride tablets,
n-dodecyl -D-maltoside (DM), andmonoclonal mouse anti-c-
Myc Ab (M4439, clone 9E10) were purchased from Sigma.
PVDF membranes were purchased from EMD Millipore (Bil-
lerica, MA). HyBlot CL autoradiography film was purchased
from Denville Scientific (Holliston, MA). FBS was purchased
from Gemini Bioproducts (West Sacramento, CA). All other
reagents were obtained from Thermo Fisher Scientific (Wal-
tham, MA) and were of analytical grade.
Constructs and receptormutagenesis
Suppressor tRNA and azF amino-acyl tRNA synthetase plas-
mids were constructed as described previously (24). Amber
codons (TAG) were introduced in the desired location of an
N-terminal double c-Myc-labeled wild-type human GLP-1R
in the pEF5/FRT/V5-DEST destination vector (Invitrogen).
Endogenous amber codons in this construct were mutated to
opal codons (TGA), and this receptor had equivalent pharma-
cology to the unmodified human GLP-1R (data not shown).
Mutagenesis was carried out using oligonucleotides for site-
directedmutagenesis purchased fromThermo Fisher Scientific
and the QuikChange Lightning site-directed mutagenesis kit
(Stratagene) and was confirmed by automated sequencing.
Transfections and cell culture
HEK293T cells were transiently transfected in serum-free
DMEM using LipofectamineTM/PLUSTM. Wild-type human
GLP-1R, suppressor tRNA and azF amino-acyl tRNA synthe-
tase were typically transfected at a ratio of 1:10:5 (g), whereas
the amber mutant human GLP-1R, suppressor tRNA, and azF
amino-acyl tRNA synthetase were typically transfected at a
ratio of 2:2:1 (g). In all cases, the combined total of DNA per
well was 2.5 g (6-well), 625 ng (24-well), or 100 ng (96-well).
Four hours post-transfection, transfected cells were supple-
mented with serum-enriched DMEM for a final concentration
of 10% (v/v) FBS with or without 0.5 mM azF.
Photocross-linking
HEK293T cells were seeded at 8  105 cells/well in 6-well
culture plates, transiently transfected using LipofectamineTM/
PLUSTM as detailed above, and incubated for 24 h at 37 °C in 5%
CO2. 24 h post-transfection, media were replaced with 10 or
100 nM FL-conjugated exendin-4 analogues (Anaspec, Neosci-
entific) with or without increasing concentrations of unlabeled
exendin-4, each prepared in HBSS, 0.1% (w/v) BSA, 20 mM
HEPES under dim light conditions, and incubated overnight at
4 °C.
Following incubation, cells were irradiated with a Maxima
ML-3500S UV-A light (Spectronics Corp.) for 2 min at 4 °C on
ice. Cells were then centrifuged at 850  g for 5 min, and the
pellet was resuspended in solubilization buffer (Tris-HCl, pH
7.5, 1% DM). Solubilization was carried out for 1 h at 4 °C on a
nutating mixer (Thomas Scientific) followed by centrifugation
at 10,000 g for 15 min at 4 °C to isolate proteins (supernatant
fraction) from cellular debris (pellet).
Immunoprecipitation
Wild-type human GLP-1R or amber mutant GLP-1Rs,
labeled with a C-terminal V5 epitope, were immunopurified
from detergent-solubilized cell lysates using Dynabeads pro-
tein G (Life Technologies, Inc.) complexed withmouse anti-V5
mAb (Life Technologies, Inc.) according to the manufacturer’s
instructions. Briefly, Dynabeads protein G were complexed
with anti-V5 for 10min at room temperature, followed by incu-
bation with cell lysates for 10 min at room temperature. V5-la-
beled proteins were eluted using 50 mM glycine, pH 2.8, for 10
min at room temperature.
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Immunoblotting
Immunopurified proteins were mixed with 4 NuPAGE
LDS Sample Buffer (Life Technologies, Inc.) andDTT (100mM)
prior to separation on NuPAGE 4–12% BisTris gels (Life
Technologies, Inc.) using NuPAGE MES SDS Buffer (Life
Technologies, Inc.) with NuPAGE antioxidant (Life Technol-
ogies, Inc.) at 160 V for70min on ice. Gel-separated proteins
were transferred to PVDFmembranes (EMDMillipore) at 18 V
for 45 min at room temperature using a semidry transfer appa-
ratus (Bio-Rad). Membranes were incubated in blocking buffer
(5% (w/v) nonfat dry milk in TBS-T (10 mM Tris-HCl, 150 mM
NaCl, 0.05% (v/v) Tween 20, pH 7.4)) for 2 h at room tempera-
ture with gentle agitation, followed by primary Ab (diluted in
blocking buffer 1:3000 for anti-FL and 1:5000 for anti-V5) over-
night at 4 °C on a nutating mixer (Thomas Scientific). The fol-
lowing day, membranes were washed with TBS-T and incu-
bated with HRP-linked secondary Ab (diluted in blocking
buffer 1:10,000) for 1 h at room temperature with gentle agita-
tion. Membranes were again washed with TBS-T, treated with
chemiluminescent substrate (Thermo Fisher Scientific) for 3
min at room temperature, and exposed to HyBlot CL autora-
diography film (Denville Scientific). Densitometry analysis of
immunoblots was performed using ImageJ 1.48 software
(National Institutes of Health). Relative cross-linking of FL-la-
beled exendin-4 peptides to receptor mutants was determined
as a measure of optical density, normalized to the respective
controls on the same blot.
cAMP accumulation assay
HEK293T cells were seeded at 2  104 cells/well in 96-well
poly-D-lysine (PDL)-coated culture plates, transiently trans-
fected using LipofectamineTM/PLUSTM as detailed above, and
incubated for 48 h at 37 °C in 5% CO2. Ligand-mediated cAMP
generation was then carried out as described previously (35).
All values were converted to concentration of cAMP using a
cAMP standard curve performed in parallel, and data were sub-
sequently normalized to the response of 10M forskolin at each
receptor mutant.
Cell-surface receptor expression
HEK293T cells were seeded at 2  105 cells/well in 24-well
PDL-coated culture plates, transiently transfected using Lipo-
fectamineTM/PLUSTMas detailed above, and incubated for 48 h
at 37 °C in 5% CO2. Cells were washed three times in PBS and
fixedwith 4% paraformaldehyde for 15min at 4 °C. Cell-surface
receptor expressionwas thenmeasured as described previously
(56). All data were normalized to the basal fluorescence
detected in mock-transfected HEK293T cells (pcDNA, tRNA
suppressor, and azF amino-acyl tRNA synthetase only).
Data analysis
All data were analyzed using Prism 6.0 (GraphPad Software
Inc., SanDiego). For all analyses, the datawere unweighted, and
each y value (mean of replicates for each individual experiment)
was considered an individual point. Concentration-response
signaling data were analyzed using Equation 1, as described
previously (57),
Y	 bottom
(top bottom)
1 10(logEC50 log
A)
(Eq. 1)
where bottom represents the y value in the absence of ligand(s);
top representsmaximal stimulation in the presence of ligand(s);
[A] is the molar concentration of ligand, and EC50 is the molar
concentration of ligand required to generate a response halfway
between top and bottom. AzF-dependent cell-surface expres-
sion of amber mutants was determined by correcting for
expression measured in the absence of azF. Accordingly, azF-
dependent expression included propagation of errors from
bothazF andazF conditions.
Statistics
Changes in total cell-surface expression for each mutant in
the absence and presence of azF was determined using an
unpaired t test, and statistical significance accepted as p 0.05.
Changes in peptide potency, efficacy, and azF-dependent
cell-surface expression of azF-incorporated human GLP-1R
mutants in comparison to wild-type human GLP-1R control
were statistically analyzed with one-way analysis of variance
and Dunnett’s post-test, and statistical significance accepted as
p 0.05.
Molecularmodeling
Modeling the human GLP-1R in complex with exendin—The
intact active-state model of the human GLP-1R in complex
with exendin-4 and the C-terminal helix of Gs was modeled
using a refined and experimentally validated model of the
GLP-1R in complex with GLP-1 as a template (38, 39). One
hundred models were generated with Modeler (58), and the
best ranked models were selected with the discrete optimized
protein energy scoring function (59) and visually inspected.
The selected model was embedded in a lipidic bilayer and sim-
ulated for 0.5 s as described under “Molecular Dynamics
Simulations.”
Molecular dynamics simulations—Simulations were pre-
pared as described previously (38, 39). Briefly, the full active-
state model of the human GLP-1R in complex with exendin-4
was immersed in a lipidic bilayer of palmitoyl oleoyl phosphati-
dylcholinewith explicitwater and ions at a concentration of 150
mM and simulated using ACEMD (60), the AMBER 14SB (61),
and lipid 14 force fields (62). The system was composed of
92,776 atoms, and the starting system dimensions were 85 
86 138 Å. The simulation procedure was composed of steps
of energyminimization, heating from 0 to 300 K, and a progres-
sive decrease of conformational constraints followed by the
unconstrained production run over 0.5 s.
Modeling of a TM4-TM4 dimer and a dimer of dimers of the
human GLP-1R—Two monomers of the active-state human
GLP-1R receptor bound to exendin-4 were modeled as a
homodimer with a TM4/TM4 interface, with the assistance of
the graphical user interface (GUI) of Maestro (Schro¨dinger
LLC). The modeled dimer satisfies experimental constraints
since the residues Gly-275, Leu-279, and Val-282, which were
reported to disrupt theGLP-1Rdimer formationwhenmutated
(40), are oriented and clustered facing one another at the inter-
face of the dimer (Fig. 6B). This dimeric model of the GLP-1R
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was used as a search unit for a novel dimer of dimers interface
that would satisfy the cross-linking data for residues on the
back side of theN-terminal ECD.Using theGUI, a newdimer of
dimers arrangement that satisfies the constraints of the cross-
linking results was identified.
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